Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
New GPNMB‑CAR‑T therapy shows promise against the deadliest brain cancer, glioblastoma.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A dual tumour–myeloid targeting approach using GPNMB CAR‑T cells is being reported as a potential treatment for aggressive glioblastoma. The strategy combines CAR‑T cell engineering with cytokine armouring to attack both tumor cells and supporting immune cells.
Coverage highlights the therapy's promise to eliminate the aggressive brain tumor, noting its innovative immunotherapy design. Outlets including News‑Medical, Labmate‑Online, Medical Xpress, The Telegraph and Nature all emphasize the potential impact on the deadliest form of brain cancer.
Future reporting will need to clarify the stage of development, efficacy data and any clinical trial outcomes, as current coverage does not specify these details.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 139d ago.
Quick answers
What type of treatment is being discussed?
The reports focus on a CAR‑T cell immunotherapy that targets GPNMB and includes cytokine armouring.
Which cancer is the therapy aimed at?
All sources refer to aggressive glioblastoma, described as the deadliest brain cancer.
What aspect of the therapy is highlighted by the coverage?
The dual tumour–myeloid targeting strategy and its potential to eliminate the tumor are emphasized.
Coverage (15)
- Beeta Benjy: What is the Missing Puzzle Piece of CAR-T Therapy Failure in Solid Tumors? Oncodaily · 139d ago
- Engineered Immunotherapy Improves Treatment for Brain Cancer Labroots · 139d ago
- CAR T Cells Simultaneously Target Glioblastoma and Immune Cells Inside Precision Medicine · 139d ago
- New Therapy Could Target One of the Deadliest Brain Cancers Newsweek · 139d ago
- Community giving powers a UCalgary cancer immunotherapy breakthrough University of Calgary · 139d ago
- New immunotherapy developed at the University of Calgary being used to treat solid cancerous tumours University of Calgary · 139d ago
- With GPNMB, CAR T makes further inroads in solid tumors BioWorld News · 139d ago
- U of C-developed experimental treatment reduces rare cancerous tumours Calgary Herald · 139d ago
- Immunotherapy Strategy Shows Promise for Deadly Brain Cancer Northwestern University · 139d ago
- McMaster-Developed Immunotherapy Strategy Targets Aggressive Brain Tumours and Their Fuel Newswise · 139d ago
- CAR-T cell therapy shows potential to eliminate aggressive glioblastoma News-Medical · 139d ago
- Cytokine-armoured CAR T therapy shows promise against aggressive glioblastoma Labmate-Online · 139d ago
- New immunotherapy strategy targets aggressive brain tumors and their immune cell accomplices Medical Xpress · 139d ago
- Deadliest brain cancer could be treated with immunotherapy The Telegraph · 139d ago
- Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells Nature · 139d ago
Topics
Related trends
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
MedPacto reported that its experimental drug MP010 eliminated 75% to 87.5% of aggressive pancreatic tumors in mice.
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
Decoding the regulatory programs governing glioblastoma plasticity
Recent scientific studies examine how glioblastoma cancer cells switch identities and navigate complex spatial architectures.
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
Cancer vaccines emerge as a major focus for the N.I.H. through a newly announced public-private partnership.